Search research articles
Contact Us
Filters
Showing results (41-50 of 54) with videos related to
Page
of 6
Sort By:
Proceedings of the National Academy of Sciences of the United States of America
|
July 13, 2000
A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin
K Mishima, A P Mazar, A Gown, et al.
Journal of Medicinal Chemistry
|
February 2, 1996
Novel N6-(substituted-phenylcarbamoyl)adenosine-5'-uronamides as potent agonists for A3 adenosine receptors
P G Baraldi, B Cacciari, G Spalluto, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 6, 1996
Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor
S Y Cheng, H J Huang, M Nagane, et al.
Journal of Medicinal Chemistry
|
May 12, 1995
Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors
K A Jacobson, S M Siddiqi, M E Olah, et al.
Nucleosides, Nucleotides & Nucleic Acids
|
September 21, 2001
Ribose modified nucleosides and nucleotides as ligands for purine receptors
K A Jacobson, R G Ravi, E Nandanan, et al.
Zhonghua Yi Xue Za Zhi
|
March 5, 2019
[The correlation between findings of whole-body diffusion weighted imaging and clinical result in patients with multiple myeloma]
W Y Huang, M Yang, W W Sui, et al.
The Journal of Biological Chemistry
|
January 31, 1997
The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling
H S Huang, M Nagane, C K Klingbeil, et al.
Journal of Medicinal Chemistry
|
March 4, 1994
Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists
C Gallo-Rodriguez, X D Ji, N Melman, et al.
Journal of Medicinal Chemistry
|
March 31, 1995
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors
S M Siddiqi, K A Jacobson, J L Esker, et al.
Journal of Medicinal Chemistry
|
October 30, 1992
Synthesis and biological activity of N6-(p-sulfophenyl)alkyl and N6-sulfoalkyl derivatives of adenosine: water-soluble and peripherally selective adenosine agonists
K A Jacobson, O Nikodijevic, X D Ji, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 54) with videos related to
Sort By:
Page
of 6
Proceedings of the National Academy of Sciences of the United States of America
|
July 13, 2000
A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin
K Mishima, A P Mazar, A Gown, et al.
Journal of Medicinal Chemistry
|
February 2, 1996
Novel N6-(substituted-phenylcarbamoyl)adenosine-5'-uronamides as potent agonists for A3 adenosine receptors
P G Baraldi, B Cacciari, G Spalluto, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 6, 1996
Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor
S Y Cheng, H J Huang, M Nagane, et al.
Journal of Medicinal Chemistry
|
May 12, 1995
Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors
K A Jacobson, S M Siddiqi, M E Olah, et al.
Nucleosides, Nucleotides & Nucleic Acids
|
September 21, 2001
Ribose modified nucleosides and nucleotides as ligands for purine receptors
K A Jacobson, R G Ravi, E Nandanan, et al.
Zhonghua Yi Xue Za Zhi
|
March 5, 2019
[The correlation between findings of whole-body diffusion weighted imaging and clinical result in patients with multiple myeloma]
W Y Huang, M Yang, W W Sui, et al.
The Journal of Biological Chemistry
|
January 31, 1997
The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling
H S Huang, M Nagane, C K Klingbeil, et al.
Journal of Medicinal Chemistry
|
March 4, 1994
Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists
C Gallo-Rodriguez, X D Ji, N Melman, et al.
Journal of Medicinal Chemistry
|
March 31, 1995
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors
S M Siddiqi, K A Jacobson, J L Esker, et al.
Journal of Medicinal Chemistry
|
October 30, 1992
Synthesis and biological activity of N6-(p-sulfophenyl)alkyl and N6-sulfoalkyl derivatives of adenosine: water-soluble and peripherally selective adenosine agonists
K A Jacobson, O Nikodijevic, X D Ji, et al.
Page
of 6